Spero Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SPRO Nasdaq 2836 sperotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spero Therapeutics, Inc.

Promising Penny Stocks To Consider In May 2026 - May 15th, 2026 6:05 am
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update - May 13th, 2026 2:05 pm
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization - Apr 22nd, 2026 4:03 pm
Uncovering 3 Penny Stocks With Market Caps Under $700M - Apr 8th, 2026 12:05 pm
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - Mar 26th, 2026 2:05 pm
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 - Mar 18th, 2026 2:05 pm
Airgain And 2 Other Promising Penny Stocks - Feb 5th, 2026 11:06 am
3 Promising Penny Stocks With Market Caps Up To $300M - Jan 7th, 2026 11:05 am
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis - Dec 19th, 2025 6:00 am
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Dec 15th, 2025 3:20 am
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 28th, 2025 6:00 am
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update - Nov 13th, 2025 2:05 pm
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 - Nov 4th, 2025 2:05 pm
3 Promising Penny Stocks With Market Caps Over $20M - Nov 4th, 2025 11:05 am
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - Oct 21st, 2025 12:00 am
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - Oct 14th, 2025 6:00 am
Best Momentum Stock to Buy for October 10th - Oct 10th, 2025 8:00 am
October 2025's Promising Penny Stocks To Consider - Oct 6th, 2025 12:05 pm
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer - Sep 4th, 2025 5:00 am
ATA Creativity Global And Two Other Promising Penny Stocks - Sep 1st, 2025 12:04 pm